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Opea b s t r a c t
Objective: To determine the feasibility of implementing a large-scale primary care-based diabetes pre-
vention trial.
Methods: A feasibility cluster randomized controlled trial was conducted in British Columbia, Canada,
amongst adults with prediabetes using the Facilitated Lifestyle Intervention Prescription (FLIP) vs. usual
care. FLIP included lifestyle advice, a pedometer, and telephone support from a lifestyle facilitator for
6 months. Indicators of feasibility included recruitment rates of family practices, participants and
facilitators, as well as feasibility and retention rates in the FLIP program and study protocols.
Results: Six family practices participated; 59 patients were enrolled between October 2012 andMarch 2013.
The trial protocol was acceptable to practices and participants and had a 95% participant retention rate over
the 6 months (56/59). Adherence to the intervention was high (97%), with 34 of 35 patients continuing to
receive telephone calls from the facilitator for 6 months. The mean cost of the intervention was C$144 per
person.Comparedwith control, interventionparticipants signiﬁcantly reducedweightby3.2 kg (95%CI,1.7 to
4.6); body mass index by 1.2 (95% CI, 0.7 to 1.7) and waist circumference by 3 cm (95% CI, 0.3 to 5.7).
Conclusions: It is feasible to implement FLIP and to conduct a trial to assess effectiveness. A larger trial
with longer follow up to assess progression to diabetes is warranted.
 2015 Canadian Diabetes Association
r é s u m é
Objectif : Déterminer la faisabilité de mettre en place un essai à grande échelle sur la prévention du
diabète fondée sur les soins de santé primaires.
Méthodes : Un essai clinique aléatoire par grappes sur la faisabilité a été mené en Colombie-Britannique, au
Canada, auprès d’adultes souffrant d’un prédiabète en utilisant la FLIP (Facilitated Lifestyle Intervention
Prescription) vs les soins habituels. La FLIP comprenait des conseils sur le mode de vie, un pédomètre et le
soutien téléphonique d’un éducateur en mode de vie durant 6 mois. Les indicateurs de la faisabilité
comprenaient les taux de recrutement des cliniques de médecine familiale, des participants et des édu-
cateurs aussi bien que la faisabilité et les taux de rétention du programme FLIP et des protocoles d’étude.
Résultats : Six (6) cliniques de médecine familiale ont participé; 59 patients ont été inscrits entre octobre
2012 et mars 2013. Le protocole d’essai a été acceptable pour les cliniques et les participants et a eu un
taux de rétention des participants de 95 % au cours des 6 mois (56/59). L’observance de l’intervention a
été élevée (97 %), soit 34 des 35 patients qui ont continué à recevoir les appels téléphoniques de
l’éducateur durant 6 mois. Le coût moyen de l’intervention s’est élevé à 144 $ CA par personne.
Open access under CC BY-NC-ND license.MCSP, Department of Family
r, David Strangway Building,
bia V6T 1Z3, Canada.
n access under CC BY-NC-ND license.
D. Dawes et al. / Can J Diabetes 39 (2015) 111e116112Comparativement aux témoins, les participants ont signiﬁcativement réduit leur poids de 3,2 kg (IC à 95
%, 1,7 à 4,6), leur indice de masse corporelle de 1,2 (IC à 95 %, 0,7 à 1,7) et leur tour de taille de 3 cm (IC à
95 %, 0,3 à 5,7).
Conclusions : Il est possible de mettre en place la FLIP et de réaliser un essai pour évaluer l’efﬁcacité. Un
essai plus vaste associé à un suivi plus long pour évaluer la progression du diabète est justiﬁé.
 2015 Canadian Diabetes Association Open access under CC BY-NC-ND license.1 Information about the manual is available from the lead author on request.Introduction
Type 2 diabetes is an increasingly common chronic condition
with aworldwide prevalence estimated to reach 439million by 2030
(1). In Canada, the prevalence of diabetes will reach 3.7 million by
2018-2019. (2), with the greatest increase forecast to be amongst
adults aged 30 to 49 years in Ontario, British Columbia, Saskatch-
ewan and the Northwest Territories (2). The direct cost of diabetes
care accounts for about 3.5% of public healthcare spending in Canada,
and this is likely to rise (3). Diabetes predisposes people to cardio-
vascular, renal, neurologic and eye complications, reduces quality of
life and accounts for more than 10% of deaths in Canadian adults (2).
Those with impaired fasting glucose and/or impaired glucose toler-
ance, “prediabetes,” are at higher risk for developing both diabetes
and cardiovascular disease. Diabetes incidence in those with pre-
diabetes is 66.1 /1000 person-years, with a hazard ratio of 2.35 (95%
CI, 1.84 to 3.01) compared with individuals with normal glucose
tolerance during a median 7.8-year follow up (4). Progression from
prediabetes to diabetes can be reduced and sustained by compre-
hensive lifestyle interventions, showing a relative risk reduction of
65% (95% CI, 15% to 86%) up to 10 years postintervention (5). The
evidence from efﬁcacy trials of lifestyle interventions supports their
translation into implementation trials and scaling up for widespread
adaption within speciﬁc contexts (6). However, the high costs and
context-speciﬁc nature of the programs present barriers to wide-
spread dissemination and implementation (6,7).
The Facilitated Lifestyle Intervention Prescription (FLIP) is a low-
cost program in primary care designed for those with prediabetes.
Weconducted apilot study toobtaindata concerning the feasibilityof
implementing FLIP to prevent progression from prediabetes to dia-
betes in Canadian primary care settings. We aimed to collect data to
aid in study design, considering processes, resources, management
and scientiﬁc reasons that would lead to a more deﬁnitive trial (8).
This is translational research, implementing existing efﬁcacy evi-
dence into everyday primary care where evidence, to date, is sparse.
Methods
Design and setting
This was a community-based feasibility cluster, randomized
controlled trial with the family practice as the unit of randomiza-
tion. The cluster design was selected to prevent potential contam-
ination of intervention between participants, because members of
the same family or friends may be recruited into the study. Family
practices, recruited from rural, urban and ethnically diverse com-
munities across British Columbia, were randomly assigned (central
number generator) to FLIP intervention or usual care. Family phy-
sicians were asked to recommend people suitable to be trained as
lifestyle-change facilitators for their patients.
Study participants
Potential study participants were identiﬁed by family physicians
using an algorithm in the electronic health record or opportunis-
tically. The algorithm generated a list of adults (aged 18 years)
who had glycated hemoglobin (A1C) in the range of 5.7% to 6.4%,
and/or fasting blood glucose levels of 6.1 to 6.9 mmol/L, and/or2-hour 75 g oral glucose tolerance test levels of 7.8 to 11.0 mmol/L
within the past year, according to the American Diabetes Associa-
tion deﬁnition for prediabetes at the time of study design. The
study excluded subjects with type 1 or 2 diabetes, unstable angina,
uncontrolled congestive heart failure, unstable arrhythmia, heart
valve disease, severe hypertension (systolic 200 mm Hg or dia-
stolic 120 mm Hg), pregnant women, those with life expectancy
<1 year, those waiting for major surgery, and those at high risk for
fracture. Recruitment letters were sent from the patients’ family
physicians to eligible patients, and follow-up telephone calls were
made by study personnel.
Intervention and control treatments
The FLIP program was designed following a review of current
evidence (5,9e23) and was informed by focus groups that included
local family physicians. FLIP consisted of 3 elements: 1) lifestyle
prescription; 2) a pedometer; and 3) support by a community-
based facilitator for 6 months.
The lifestyle prescription comprised brief advice and a statement
of intent to modify health behaviour, including long-term goals for
healthy eating, weight and physical activity. The prescription was
based on Canadian recommendations for healthy eating and activity
(24,25). It was agreed upon, completed and signed by both the
physicians and the participants, with copies for the patients, physi-
cians and lifestyle change facilitators. The patients were also offered
pedometers to use as an aid to increasing physical activity.
The lifestyle change facilitators contacted the participants by
telephonewithin 10 days of their receiving the lifestyle prescription.
Telephone calls, based on motivational interviewing techniques (26)
were made twice per month for 6 months to aid the participants in
forming, attaining and sustaining sequential short-term goals and
were conducted according to the intervention manual developed by
the research team.1 Facilitators were trained for 1 week by the lead
author prior to the study. Every call was tailored to the individual
participants using the readiness for behaviour change model (27) to
engage and evoke their motivations for change, clarify their
strengths and aspirations and weekly successes, and promote au-
tonomy of decision making. The subjects, supported by the facilita-
tors, developed their plans, introducing changes in eating habits and
engagement in both aerobic and resistance activity. Through
attaining these short-term goals, it was anticipated that they would
achieve the long-term healthy eating, weight and physical activity
goals agreed upon in the prescriptiondthe goals that conform to the
Canadian recommendations (24,25).
Control participants received usual care from their family
practice physician, consistent with Canadian Diabetes Association
guidelines (28).
Outcomes
Indicators of feasibility included recruitment rates of family
practices, participants and facilitators, as well as feasibility and
retention rates in the FLIP program and study protocols. Costs of the
program delivery were collected.
7 family practices 
approached
6 family practices 
recruited
Randomization of 
practices: 
3 intervention 
3 control
180 recruitment letters 
mailed to eligible 
participants
35 recruited to 
intervention 
2 lost to
follow-up
Completed 6-
month assessment 
n = 33
24 recruited to 
control
1 lost to
follow-up
Completed 6-
month assessment 
n = 23
Figure 1. Flow of participants through the study. Participants in the control group
received usual care, and participants in the intervention group received facilitated
lifestyle interventions.
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at 6 months by assessors, using standardized protocols. Clinical
outcomes included weight, height, waist circumference, blood
pressure, A1C, fasting glucose, lipids, physical activity levels, exer-
cise endurance and quality of life.
Height, weight and waist circumference were measured by
study staff using standard protocols (29). Blood pressure was
assessed using a semiautomated, validated sphygmomanometer
(BpTRUMedical Devices, Coquitlam, British Columbia, Canada) that
takes 6 readings and calculates the mean, having discarded the ﬁrst
reading (30). Physical activity was assessed using the Godin
Leisure-Time Exercise Questionnaire (31). Exercise endurance was
measured using the 2-minute walk test, a submaximal functional
test of walking endurance (32). Quality of life was assessed using
the EuroQoL Health Questionnaire (EQ5D) (33,34) and the Short-
Form Health Survey-36 (SF-36) (35). Data collected included
demographic details and usual diet using the Food Frequency
Questionnaires (FFQs) (36). Participants were also asked, at the
6-month visit, whether they had experienced a musculoskeletal
injury while they had been in the study, and what costs they had
incurred during participation.
Ethics approval
The trial was approved by the Research Ethics Board of the
University of British Columbia and registered at www.clinicaltrials.
gov (NCT01589835).
Statistical analysis
Baseline characteristics were summarized, including the Cana-
dian Diabetes Risk Assessment (CANRISK) score, incorporating age,
BMI, waist circumference, hypertension and family history of dia-
betes (37). All participants with data at baseline and 6 months were
included in the analyses of clinical variables. We compared within-
patient change from baseline to 6 months in the intervention vs.
control groups in the study outcome measures using the Student
paired t test. A chi-square test for the difference between groupswas
used for weight reduction greater than 5% of body weight. We used
the large 1-way ANOVA (loneway) command in Stata 13.1 (Stata-
Corp, College Station, Texas, USA), which uses an analysis of variance
to create the intraclass correlation (ICC) and 95% conﬁdence interval.
The analysis was run on intervention and control practices sepa-
rately so as to explore practice level impact on the differences in
outcomes. Adjustment for clustering by family practice was not
carried out during the pilot but is planned for the full trial.
Sample size
The sample size calculations for this cluster randomized trial
indicate that using alpha ¼ 0.05, beta ¼ 0.1 to demonstrate effec-
tiveness for proportions of patients converting to diabetes,
including adjustment for ICC (d effect size) 0.05 (1.45), it would be
necessary to recruit 670 patients from 67 clinics. Because this is a
pilot, we aimed to enrol a mean of 10 patients from 6 clinics, for a
total of 60 patients. This was thought to be sufﬁcient to test feasi-
bility, the aim of the pilot study.
Results
Feasibility indicators
Between June 2012 and February 2013, 7 family practices in
British Columbia were approached, all of which agreed to partici-
pate; 6 went on to recruit patients between October 2012 and
March 2013, and 1 agreed to do so in the future. Letters weremailedto 180 eligible people, of whom 59 (33%) made appointments for
baseline assessment and consented to participate (Figure 1). Of
these, 35 were in intervention practices and 24 in control practices.
The trial protocol was acceptable to practices and participants and
had a 95% participant retention rate over the 6 months (56/59).
Three facilitators were recruited and trained in interviewing and
goal-setting techniques; all facilitators were retained throughout
the study. They included a primary care chronic disease manage-
ment nurse, a bilingual (Punjabi and English) registered dietitian,
and an undergraduate who was majoring in psychology.
Retention and adherence to the interventionwere high. Of those
receiving the intervention, one was lost to follow up through
moving to another province, one completed the intervention but
did not have the 6-month assessment due to being “overwhelmed
by life events,” and one requested to stop receiving the telephone
calls from the facilitator but agreed to have the 6-month
assessment.
Table 1
Baseline characteristics of British Columbian study participants
FLIP group
(n¼35)
Control
group
(n¼24)
All participants
(n¼59)
Sex, male; n (%) 20 (57) 10 (42) 30 (51)
Age, years; n (%)
35-44 4 (11) 2 (8) 6 (10)
45-54 6 (17) 3 (12) 9 (15)
55-64 10 (29) 3 (12) 13 (22)
65 15 (43) 16 (67) 31 (53)
Ethnic group: n (%)
Caucasian 19 (54) 22 (92) 41 (69)
Latin American 0 1 (4) 1 (2)
Asian 16 (46) 1 (4) 17 (29)
BMI, kg/m2 mean (SD) 29.1 (4.5) 29.7 (5.8) 29.1 (5.9)
Comorbidity questionnaire; n (%)
Hypertension 14 (40) 10 (42) 24 (41)
Previous stroke 0 0 0
Asthma 0 0 0
Current smoker 0 0 0
CANRISK scorea mean (SD) 13.0 (4.1) 12.2 (4.0) 12.7 (4.1)
a Canadian Diabetes Risk Assessment: scored 0 to 26; 12 to 14¼moderate risk for
developing type 2 diabetes.
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C$144, composed mostly of pedometers (C$35); family physician
visits (C$50) and facilitator calls (C$58).
Baseline characteristics
The practices were equally distributed according to setting, with
1 practice in each arm in rural, deprived suburb and high-income
settings. The 2 groups had similar characteristics at baseline apart
from ethnicity (Table 1). One solo family practice serves a pre-
dominately Punjabi population, meaning that 46% of the inter-
vention group was of Asian ethnicity. The other practices work in
groups of more than 4 family physicians, one run by residents
serving a largely university population, a Community Health Centre
in Vancouver Eastside, a teaching clinic in an afﬂuent area of
Vancouver, a rural practice with a nurse specializing in chronic
disease management and an interprofessional rural teaching
practice in theWest Kootenay region of British Columbia. Themean
Canadian Diabetes Risk Assessment (CANRISK) score was 12.7
(median ¼ 13; range, 4 to 23); a CANRISK score from 12 to 14
indicates a moderate risk for developing type 2 diabetes (37).
Clinical measures
At 6 months, the mean differences in the A1C levels from
baseline to 6 months was a reduction of 0.07% (SD 0.21) in the FLIP
group vs. an increase of 0.03% (SD 0.24) in the control group, with a
nonsigniﬁcant between-group difference of 0.1% (95% CI, 0.03 to
0.23) in favour of FLIP patients (Table 2). Two patients in the control
group but none in the intervention group moved from prediabetic
states to having A1C levels above 6.5%, indicating a shift to the
diagnosis of diabetes.
Other ﬁndings favouring the FLIP intervention included signiﬁ-
cant reductions in weight of 3.2 kg (95% CI, 1.7 to 4.6); in BMI of 1.2
(95% CI, 0.7 to 1.7); and in waist circumference of 3 cm (95% CI, 0.3
to 5.7); and increased exercise endurance of 14.1 m (95% CI, 3.1 to
25.1) compared with the control group. The intervention group
increased their physical activity levels, with a rise in Godin leisure
time activity scores of 29.6 points (SD 30.2) vs. 5.1 points (SD 23.3)
in the control group and a between-group difference of 24.5 points
(95% CI, 39.6 to 9.5). Differences in systolic and diastolic blood
pressure and quality of life did not reach statistical signiﬁcance at
the conventional levels.Adverse effects
In the control and intervention groups, 7 (30%) and 4 (12%)
subjects, respectively, reported a musculoskeletal injury during the
6 months of the study. No injuries were stated to have occurred as a
direct result of participating in the study.
Discussion
It was possible to recruit 6 family practices, 3 community-based
intervention facilitators and 59 study participants within 7 months
from geographically and ethnically diverse populations. Retention
rates in the study over 6 months were excellent (95%). The study
protocol was implemented in a standard way across practices.
The results of our study suggest that a 6-month facilitated life-
style intervention designed to decrease progression to diabetes, as
well as diabetes risk factors, is feasible, and changes in clinical
measures in the intervention group were very promising compared
with the control group, despite the study’s not being powered to
show statistically signiﬁcant differences. We saw some cluster
variation, as shown by the ICC calculations, that suggest a need to
adjust some results for design effect for some of the outcomes in
future studies. Because this is a pilot study, we did not calculate or
adjust the t test for design effect with so few clusters.
It is not known whether the changes were sustained beyond the
study period and, anecdotally, patients would have liked the inter-
vention to have been longer than 6 months. We plan to extend the
facilitator telephone support to 12 months in the subsequent main
trial. Long-term beneﬁt should then be measured for up to 5 years
because this would reﬂect conversion to diabetes. Other diabetes
prevention programs have varied in intensity and length of interven-
tion. The GrOup-based physical Activity for oLder adults (GOAL) trial
was group based and included ﬁve 2-hour sessions delivered over
8 weeks and 1 booster session at 8 months, with outcomes measured
at 1 and 3 years (38). In comparison, the Finnish Diabetes Prevention
Study (FinDPS) had a median number of 20 individual 30- to
60-minute counselling sessions; themedian lengthof the intervention
was 4 years, and the mean duration of follow up was 3.2 years (23).
Other trials have demonstrated that programs focused on
modifying lifestyle can contribute to a signiﬁcant reduction in the
risk for diabetes (16,21,23). Many of these efﬁcacy studies have used
high-cost, intensive, individualized counselling delivered by highly
trained health professionals. These are major limitations for uptake
in healthcare systems when there is such high prevalence. We
evaluated an intervention that does not require high cost or highly
trained health professionals for implementation.
We found a signiﬁcant weight change between groups of 3.2 kg
(95% CI, 1.7 to 4.6) at 6months, which is similar to theweight change
of 3.4 kg (95%CI, 2.6 to 4.2) observedbyTuomilehto (23) at 1 year; the
3.8 kg (95% CI, 2.5 to 5.1) found by Eriksson (39) at 1 year; the 1.4 kg
(95% CI, 0.9 to 1.9) found by Saito (22) at 1 year; the 4.19 kg (0.71)
found by Katula (40) over 18 and 24 months of follow up and the
approximately 7 kg change found by Knowler (16) at 6 months. The
FLIP study showed a signiﬁcant decrease inwaist circumference of 3
cm (95% CI, 0.3 to 5.7) at 6 months. This is also similar to the 3.1 cm
(95% CI, 2.2 to 4.0) (23); the 3.5 cm (95% CI 2.2 to 4.8) (39); the 1.8 cm
(95% CI, 1.1 to 2.5) (22) at 1 year and the 3.23 cm (0.69) over 24
months (40) found in previous trials. Although we would have ex-
pecteda largerdifference inA1Cbetween thegroups, the trendwas in
the right direction, and this study was not powered to detect a 0.1%
difference as being statistically signiﬁcant.
The direct medical cost of diabetes in the United States in 2007
was estimated tobeUS$116 billion (41). Themean cost of FLIP for the
6-month interventionwas C$144 per person; this is less than the US
lifestyle intervention for the diabetes prevention program (DPP)
that cost approximately US$1400 per person in its ﬁrst year and
Table 2
Comparison of change in study outcomes in facilitated lifestyle intervention group and control group from baseline to 6 months
Outcome, units FLIP Intervention, mean (SD)a n¼33 Control group, mean (SD)a n¼23 FLIP v Control FLIP Practices Control Practices
Baseline 6 month Change Baseline 6 month Change Change (95% CI) ICC (95% CI) ICC (95% CI)
A1Cc, % 5.97 (0.34) 5.89 (0.31) 0.07 (0.21) 5.9 (0.29) 5.93 (0.29) 0.03 (0.24) 0.10 (0.03 to 0.23) 0.00 (0 to 0.32) 0.01 (0 to 0.31)
A1C shift to 6.5, n (%) 0 (0) 2 (9)
Weight, kg 81.0 (14.5) 77.6 (13.4) 3.4 (3.1) 81.5 (15.4) 81.2 (15.5) 0.3 (1.8) 3.2 (1.7 to 4.6) 0.00 (0 to 0.19) 0.00 (0 to 0.28)
Weight reduction >5%, n (%) 12 (36) 1 (4) p < 0.01b
Body mass index 29.4 (4.5) 28.2 (4.1) 1.2 (1.1) 29.6 (5.9) 29.6 (5.9) 0 (0.7) 1.2 (0.7 to 1.7) 0.00 (0 to 0.19) 0.00 (0to 0.27)
Waist circumference, cm 99 (9.4) 95 (9) 4 (5) 100.6 (13.6) 99.6 (12.9) 1 (5) 3 (0.3 to 5.7) 0.01 (0to 0.23) 0.06 (0 to 0.41)
Systolic BP, mm Hg 128 (19) 120 (15) 8 (16) 125 (15) 124 (16) 1 (12) 7 (14.9 to 0.9) 0.00 (0 to 0.19) 0.06 (0 to 0.42)
Diastolic BP, mm Hg 81 (10) 76 (9) 4 (9) 78 (10) 76 (12) 2 (7) 2 (6.5 to 2.5) 0.14 (0 to 0.54) 0.04 (0 to 0.38)
2-minute walk test, m 167.9 (35.9) 173.9 (43.4) 6.0 (21.8) 170.4 (43.6) 162.4 (39.7) 8.1 (17.6) 14.1 (3.1 to 25.1) 0.00 (0 to 0.19) 0.00 (0 to 0.14)
Godin activity score 28.9 (22.6) 58.5 (29.8) 29.6 (30.2) 30.7 (17.8) 35.8 (16.0) 5.1 (23.3) 24.5 (9.5 to 39.6) 0.09 (0 to 0.41) 0.00 (0 to 0.27)
Fasting glucosed, mmol/L 6.19 (0.54) 5.96 (0.52) 0.22 (0.41) 5.72 (0.67) 5.69 (0.63) 0.03 (0.47) 0.18 (0.42 to 0.06) 0.00 (0 to 0.22) 0.00 (0 to 0.27)
HDL cholesterole, mmol/L 1.32 (0.4) 1.41 (0.5) 0.09 (0.39) 1.49 (0.35) 1.55 (0.36) 0.06 (0.16) 0.03 (0.15 to 0.21) 0.12 (0 to 0.51) 0.29 (0 to 0.87)
LDL cholesterole, mmol/l 3.02 (0.95) 3.13 (0.96) 0.11 (0.56) 2.68 (0.97) 2.89 (1.14) 0.21 (0.53) 0.10 (0.43 to 0.22) 0.00 (0 to 0.21) 0.59 (0 to 1.2)
Total cholesterole, mmol/l 5.14 (0.9) 5.14 (1.04) 0.00 4.67 (1.21) 4.8 (1.24) 0.12 (0.7) 0.13 (0.52 to 0.26) 0.00 (0 to 0.21) 0.13 (0 to 0.60)
EQ-5D, VAS score 83 (12) 86 (9) 3 (10) 79 (11) 84 (9) 5 (8) 2 (7 to 3) 0.00 (0 to 0.19) 0.00 (0 to 0.27)
SF-36 scales
Physical functioning 90 (10) 92 (8) 1.4 (6.7) 83 (20) 84 (19) 0.2 (17.9) 1.1 (5.4 to 7.7) 0.00 (0 to 0.19) 0.12 (0 to 0.55)
Emotional well-being 80 (18) 87 (12) 7 (11) 76 (17) 81 (14) 6 (15) 1 (6 to 8) 0.06 (0 to 0.35) 0.09 (0 to 0.48)
General health 76 (18) 82 (15) 6 (15) 71 (12) 74 (17) 3 (13) 3 (5 to 11) 0.38 (0 to 0.95) 0.00 (0 to 0.27)
BP, blood pressure; EQ-5D, EuroQoL Group form; FBG, fasting blood glucose; FLIP, Facilitated Lifestyle Intervention Prescription; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; SF-36, Short-Form Health Survey-36; VAS, visual analogue scale.
a Unless otherwise stated
b Chi-square test for the difference between groups
c A1C results were available at baseline and 6 months for 26 patients in the intervention sites and 22 patients in the control sites.
d FBG results were available at baseline and 6 months for 32 patients in the intervention sites and 23 patients in the control sites
e Cholesterol results were available at baseline and 6 months for 31 patients in the intervention sites and for 22 patients in the control sites.
D. Dawes et al. / Can J Diabetes 39 (2015) 111e116 115approximately US$700 per person per year thereafter (42). With
progression from impaired glucose tolerance to diabetes treated by
diet and exercise, to diabetes treated by an oral agent, to diabetes
with complications and comorbidities, there is a progressive step-
wise decrement in health-utility scores (43). The costs of treatments
for the primary prevention of type 2 diabetes range from less than
$1000 to approximately $20,000 per quality-adjusted life-year
gained (43), Given that interventions that cost less than $50,000
per quality-adjusted life-year gained are considered an appropriate
way to use resources, the FLIP intervention may be an appropriate
use of resources, should the subsequent adequately powered trial
show effective reductions in progression to diabetes.
Limitations
The ﬁndings of our feasibility trial should be interpreted with
caution because adjustment for clustering was not carried out, and
the study was not powered to show differences as statistically
signiﬁcant andwas of short duration. However, the feasibility of the
intervention and study protocol and the positive trends in out-
comes provide the necessary foundation for an adequately pow-
ered randomized trial with longer follow up in primary care.
Conclusions
In this pragmatic, feasibility, cluster randomized controlled trial
of a 6-month lifestyle intervention involving patients with pre-
diabetes seen in primary care, our trial design was shown to be
feasible, and our intervention achieved an effect that was, for some
outcomes, statistically signiﬁcant. These results provide the ratio-
nale to move forward with a larger, adequately powered trial of
facilitated lifestyle intervention prescriptions to care for people
with prediabetes.
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